Last reviewed · How we verify

Diprivan

St. Antonius Hospital · FDA-approved active Small molecule Quality 19/100

Diprivan, marketed by St. Antonius Hospital, is a general anesthetic with a well-established presence in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. However, the lack of revenue data and key trial results poses a significant risk in assessing its long-term market sustainability.

At a glance

Generic nameDiprivan
Also known asPropofol
SponsorSt. Antonius Hospital
TargetCytochrome P450 2C9, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 4
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: